Drug Trial Radar · NCT03137069
A Study of GDC-0853 in Participants With Refractory Chronic Spontaneous Urticaria (CSU).
Last checked: Nov 19, 2026Latest source record: Sep 29, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
134
Actual
Start
May 26, 2017
Primary completion
Sep 27, 2019
Study completion Oct 25, 2019
Sponsor
- Lead sponsor
- Genentech, Inc.Roche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- May 2, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of GDC-0853 compared with placebo in participants with Refractory Chronic Spontaneous Urticaria (CSU) already treated with anti-histamines. Participants have the option to enter the Open-Label Extension (OLE) study after completing the 8-week treatment period.
Conditions
- Urticaria
Interventions
GDC-0853Drug
GDC-0853 will be administered orally at dosages of 50, 150 and 200mg to participants, as per the dosing schedules described above.
PlaceboDrug
Matching Placebo will be administered orally, as per the dosing schedules described above.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in the Urticaria Activity Score Over 7 Days (UAS7) at Day 57Time frame: Baseline and Day 57
Locations
27 sites in 3 countries. Site status is shown where the registry gives one.
Clinical Research Center of Alabama, LLC
Birmingham, Alabama
Allergy & Asthma Immunology Associates
Scottsdale, Arizona
Kern Allergy Med Clinic, Inc.
Bakersfield, California
Southern California Research Center
Mission Viejo, California
Allergy & Asthma Consultants
Redwood City, California
Integrated Research Group Inc
Riverside, California
Integrated Research of Inland
Upland, California
New Horizon Research Center
Miami, Florida
Renstar Medical Research
Ocala, Florida
Vital Prospects Clinical Research Institute PC - CRN
Tulsa, Oklahoma
Asthma, Nasal Disease, and Allergy Research Center of New England
East Providence, Rhode Island
Center for Clinical Studies
Cypress, Texas
Timber Lane Allergy and Asthma Research, LLC
Burlington, Vermont
University of British Columbia
Vancouver, British Columbia, Canada
Private Practice - Dr. Jason Ohayon
Hamilton, Ontario, Canada
Lynde Institute for Dermatology
Markham, Ontario, Canada
Cheema Research
Mississauga, Ontario, Canada
Yang Medicine
Ottawa, Ontario, Canada
Gordon Sussman Clinical Research
Toronto, Ontario, Canada
Private Practice - Dr. Isabelle Delorme
Drummondville, Quebec, Canada
Centre de Recherche Applique En Allergie de Quebec
Québec, Quebec, Canada
Licca Clinical Research Institute
Augsburg, Germany
Charite Mitte; Klinik fur Dermatologie
Berlin, Germany
Universitätsklinikum Carl Gustav Carus, Klinik und Poliklinik für Augenheilkunde
Dresden, Germany
Hautarztpraxis Mahlow
Mahlow, Germany
Universitätsmedizin Johannes Gutenberg Universität
Mainz, Germany
Klinik für Haut- und Geschlechtskrankheiten, Universitätsklinikum Münster
Münster, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.